Tuesday, November 21, 2006 8:00:00 AM PDT | VentureDeal Staff
GAITHERSBURG, MD -- TissueGene, an osteoarthritis therapy biotechnology company, is close to finalizing an $18 million round of financing, according to a Biz Journal report. The company is close to beginning phase I clinical human trials of its genetic therapy drug TG-C for osteoarthritis. It is expected that the financing will assist the company in proceeding through trial to commercialization. Total funding to date with the financing will be $23 million.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
